Welcome to our dedicated page for Cerus news (Ticker: CERS), a resource for investors and traders seeking the latest updates and insights on Cerus stock.
Cerus Corporation develops and supplies blood-safety technologies and pathogen-protected blood components for blood centers and hospitals. Its recurring news centers on the INTERCEPT Blood System for platelets and plasma, the U.S. INTERCEPT Blood System for Cryoprecipitation used to produce INTERCEPT Fibrinogen Complex, and the company’s red blood cell pathogen-reduction program.
Company updates commonly cover product revenue, gross margin trends, revenue guidance, government contract activity, international supply agreements, clinical studies involving pathogen-inactivated platelets, regulatory and pipeline developments, healthcare conference participation, and governance changes. Commercial disclosures often emphasize demand for INTERCEPT Fibrinogen Complex and adoption of pathogen inactivation technologies by blood establishments in the United States, Europe and other markets.
Cerus Corporation (Nasdaq:CERS) announced notable participation at the AABB 2020 Virtual Annual Meeting, taking place from October 3-5. The event will highlight vital advancements in transfusion medicine, including 17 abstracts presented by Cerus, featuring one oral presentation on optimizing platelet supply. Key focus areas include new FDA guidance on bacterial risk control for platelets and the economic impacts of implementing INTERCEPT Blood System strategies. Cerus remains committed to improving blood safety and is poised for advancements in its clinical studies.